Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2695 SEK | +0.19% |
|
-3.58% | -97.31% |
05-22 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
05-16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.31% | 38.8M | |
+21.85% | 46.44B | |
+37.63% | 39.1B | |
-8.05% | 38.76B | |
+29.04% | 31.24B | |
-13.75% | 25.8B | |
+10.65% | 25.9B | |
+38.43% | 13.12B | |
-6.92% | 11.32B | |
-12.29% | 10.68B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Transcript : Xbrane Biopharma AB, Q2 2022 Earnings Call, Jul 22, 2022